Evidence of EZH2 dependent and independent mechanisms of tazemetostat treatment emergent resistance in models of diffuse large B cell lymphoma

被引：0
|
作者：
Campbell, Carly T.
Jasper, Jeff S.
Daigle, Scott R.
Ribich, Scott A.
Keilhack, Heike
Smith, Jesse S.
Ho, Peter T.
Blakemore, Stephen J.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-312
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
312
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas
    Bisserier, Malik
    Wajapeyee, Narendra
    BLOOD, 2018, 131 (19) : 2125 - 2137
  • [2] EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma
    Neves Filho, Eduardo Henrique
    Hirth, Carlos Gustavo
    Frederico, Igor Allen
    Burbano, Rommel Mario
    Carneiro, Thiago
    Rabenhorst, Silvia Helena
    APMIS, 2020, 128 (04) : 308 - 315
  • [3] The Histone Methyltransferase EZH2 is Required for Cell Growth in Diffuse Large B-cell Lymphoma
    Trojer, P.
    Garapaty, S.
    Lan, F.
    Balsubramanian, V.
    Chan, E.
    Hatton, C.
    Campbell, R.
    Cummings, R.
    Normant, E.
    Bryant, B.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 166 - 167
  • [4] Mutational Analysis of EZH2 in the Germinal Centre Type of Diffuse Large B Cell Lymphoma
    Abbas, Farah Fatima
    Bari, Muhammad Furqan
    Mughal, Muhammad Nouman
    Khan, Bilal Ahmed
    Khan, Nehad
    Kamil, Saba
    Razzaq, Abdul
    Kamil, Noor
    JOURNAL OF THE LIAQUAT UNIVERSITY OF MEDICAL AND HEALTH SCIENCES, 2024, 23 (01): : 15 - 20
  • [5] Dysregulation of iron homeostasis by TfR-1 renders EZH2 wild type diffuse large B-cell lymphoma resistance to EZH2 inhibition
    Lei Yu
    Ya-fang Wang
    Jian Xiao
    Qian-qian Shen
    Shuai-shuai Chi
    Ying-lei Gao
    Dong-ze Lin
    Jian Ding
    Yan-fen Fang
    Yi Chen
    Acta Pharmacologica Sinica, 2023, 44 : 2113 - 2124
  • [6] Dysregulation of iron homeostasis by TfR-1 renders EZH2 wild type diffuse large B-cell lymphoma resistance to EZH2 inhibition
    Yu, Lei
    Wang, Ya-fang
    Xiao, Jian
    Shen, Qian-qian
    Chi, Shuai-shuai
    Gao, Ying-lei
    Lin, Dong-ze
    Ding, Jian
    Fang, Yan-fen
    Chen, Yi
    ACTA PHARMACOLOGICA SINICA, 2023, 44 (10) : 2113 - 2124
  • [7] Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation
    Zhou, Zheng
    Gao, Juehua
    Popovic, Relja
    Wolniak, Kristy
    Parimi, Vamsi
    Winter, Jane N.
    Licht, Jonathan D.
    Chen, Yi-Hua
    LEUKEMIA & LYMPHOMA, 2015, 56 (10) : 2895 - 2901
  • [8] EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma
    Julia, Edith
    Salles, Gilles
    FUTURE ONCOLOGY, 2021, 17 (17) : 2127 - 2140
  • [9] Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth
    Garapaty-Rao, Shivani
    Nasveschuk, Christopher
    Gagnon, Alexandre
    Chan, Eric Y.
    Sandy, Peter
    Busby, Jennifer
    Balasubramanian, Srividya
    Campbell, Robert
    Zhao, Feng
    Bergeron, Louise
    Audia, James E.
    Albrecht, Brian K.
    Harmange, Jean-Christophe
    Cummings, Richard
    Trojer, Patrick
    CHEMISTRY & BIOLOGY, 2013, 20 (11): : 1329 - 1339
  • [10] The historic methyltransferase EZH2 catalytic activity is required for cell growth in diffuse large B-cell lymphoma.
    Audia, James E.
    Trojer, Patrick
    Garapaty, Shivani
    Lan, Fei
    Balasubramanian, Vidya
    Chan, Eric
    Hatton, Charles
    Campbell, Robert
    Cummings, Richard
    Normant, Emmanuel
    Bryant, Barbara
    Albrecht, Brian
    Harmange, Jean Christophe
    Dakin, Les
    Gehling, Victor
    Nasveschuk, Chris
    Vaswani, Rishi
    Cook, Andrew
    CANCER RESEARCH, 2013, 73 (08)
12345